

Applicants: Reiter, et al.

U. S. Serial No.: Not yet assigned

Filed: May 14, 2001

Page: 3

-- 54. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA protein so bound comprises amino acid residues 1 through 123 as described in SEQ ID NO:2. --

-- 55. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 2 through 50 as described in SEQ ID NO:2. --

-- 56. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 123 as described in SEQ ID NO:2. --

-- 57. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 109 as described in SEQ ID NO:2. --

-- 58. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 98 as described in SEQ ID NO:2. --

-- 59. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 22 through 99 as described in SEQ ID NO:2. --

-- 60. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 50 as described in SEQ ID NO:2. --

-- 61. (NEW) The anti-idiotypic antibody of claim 53 wherein the PSCA so bound comprises amino acid residues 46 through 85 as described in SEQ ID NO:2. --

-- 62. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound by the antibody which binds to a Prostate Stem Cell Antigen (PSCA) comprises amino acid residues 50 through 64 as described in SEQ ID NO:2. --

Applicants: Reiter, et al.

U. S. Serial No.: Not yet assigned

Filed: May 14, 2001

Page: 4

-- 63. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 67 through 81 as described in SEQ ID NO:2. --

-- 64. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 21 through 99 as described in SEQ ID NO:2. --

-- 65. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 71 through 82 as described in SEQ ID NO:2. --

-- 66. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 99 as described in SEQ ID NO:2. --

-- 67. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 18 through 50 as described in SEQ ID NO:2. --

-- 68. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 46 through 98 as described in SEQ ID NO:2. --

-- 69. (NEW) The anti-idiotypic antibody of claim 53, wherein the PSCA so bound comprises amino acid residues 85 through 98 as described in SEQ ID NO:2. --

-- 70. (NEW) A method for inducing an immune response in a subject, comprising administering to the subject the anti-idiotypic PSCA antibody of claim 53. --

-- 71. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 1 through 123 of PSCA as described in SEQ ID NO:2. --

Applicants: Reiter, et al.

U. S. Serial No.: Not yet assigned

Filed: May 14, 2001

Page: 5

-- 72. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 2 through 50 of PSCA as described in SEQ ID NO:2. --

-- 73. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 123 of PSCA as described in SEQ ID NO:2. --

-- 74. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 109 of PSCA as described in SEQ ID NO:2. --

-- 75. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 98 of PSCA as described in SEQ ID NO:2. --

-- 76. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 22 through 99 of PSCA as described in SEQ ID NO:2. --

-- 77. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 50 of PSCA as described in SEQ ID NO:2. --

-- 78. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 85 of PSCA as described in SEQ ID NO:2. --

Applicants: Reiter, et al.

U. S. Serial No.: Not yet assigned

Filed: May 14, 2001

Page: 6

-- 79. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 50 through 64 of PSCA as described in SEQ ID NO:2. --

-- 80. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 67 through 81 of PSCA as described in SEQ ID NO:2. --

-- 81. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 21 through 99 of PSCA as described in SEQ ID NO:2. --

-- 82. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 71 through 82 of PSCA as described in SEQ ID NO:2. --

83. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 85 through 99 of PSCA as described in SEQ ID NO:2. --

-- 84. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 18 through 50 of PSCA as described in SEQ ID NO:2. --

-- 85. (NEW) The method of claim 70, wherein the anti-idiotypic antibody binds an anti-PSCA-antibody which binds amino acid residues 46 through 98 of PSCA as described in SEQ ID NO:2. --